yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Angiogenesis
  5. EGFR

EGFR

EGFR

The epidermal growth factor receptor (EGFR; ErbB1) is a member of the epidermal growth factor RTK (receptor tyrosine kinases) family, along with HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-α), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.
The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.

EGFR related products

Structure Cat No. Product Name CAS No. Product Description
(E/Z)-AG490 V51518 (E/Z)-AG490 134036-52-5 (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is the racemate of (E)-AG490 and (Z)-AG490.
(Rac)-JBJ-04-125-02 acetate V87036 (Rac)-JBJ-04-125-02 acetate (Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02, a potent, mutant-selective, allosteric and orally active EGFR inhibitor.
(Z)-RG-13022 V88019 (Z)-RG-13022 149286-90-8 (Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits EGFR TK activity and inhibits EGF-stimulated cultured cell growth.
13(S)-HPODE V92474 13(S)-HPODE 33964-75-9 13(S)-HPODE is a linoleic acid metabolite found in some plants and mammals.
4-Methyl erlotinib V101861 4-Methyl erlotinib 1346601-52-2 4-Methylerlotinib is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
4-Methyl erlotinib (Standard) V97045 4-Methyl erlotinib (Standard) 1346601-52-2 4-Methyl Erlotinib (Standard) is the analytical standard for 4-methyl Erlotinib.
Antiproliferative agent-54 V100619 Antiproliferative agent-54 1240322-54-6 Antiproliferative agent-54 (compound 6z) is an inhibitor of multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A, and SRC, with IC50 of 6-50 nM.
Asandeutertinib V99924 Asandeutertinib 1638281-46-5 Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor effects.
AZ14133346 V89060 AZ14133346 AZ14133346 (compound 36) is a potent and selective EGFR exon 20 insertion inhibitor with IC50 of 85 nM.
Befotertinib mesylate (D-0316 mesylate) V86152 Befotertinib mesylate (D-0316 mesylate) 2226167-02-6
BI-4732 V88962 BI-4732 2769715-68-4 BI-4732 is a potent inhibitor of EGFR activating (E19del and L858R) and T790M mutations with high blood-brain barrier permeability and targets a broad range of EGFR mutations, including C797S.
Biotin HER-2 substrate peptide V88961 Biotin HER-2 substrate peptide Biotin HER-2 substrate peptide is a substrate for HER4 and HER2/NEU tyrosine kinases, with a Km value of 60 μM for the HER2/NEU kinase domain.
BPI-15086 V98031 BPI-15086 1644502-33-9 BPI-15086 is an oral, potent, irreversible, mutation-selective EGFR and T790M resistance-mutant tyrosine kinase inhibitor.
Candidalysin V87038 Candidalysin 1906866-53-2 Candidalysin is a cytolytic peptide toxin originally isolated from Candida albicans that has both toxic and non-toxic properties.
CLM3 V98985 CLM3 1312024-59-1 CLM3 is a pyrazolopyrimidine derivative and a multi-tyrosine kinase inhibitor.
DOTAGA-anhydride V96845 DOTAGA-anhydride 1375475-53-8 DOTAGA-anhydride is a DOTA-based metal chelator that can be used to bind radionuclides to prepare radionuclide conjugates (RDCs).
DS06652923 V97087 DS06652923 DS06652923 is an orally available, potent EGFR triple mutation inhibitor.
EGFR kinase inhibitor 3 V87037 EGFR kinase inhibitor 3 2922402-03-5 EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric EGFR kinase inhibitor with IC50 of <10 nM, 1.5 nM, 0.059 nM, and 0.064 nM for WT EGFR, EGFR activating mutations L858R, L858R/T790M, and L858R/T790M/C797S, respectively.
EGFR kinase inhibitor 4 V89059 EGFR kinase inhibitor 4 2922402-05-7 EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC50 is 1.8 nM for mutant EGFR (LRTMCS)).
EGFR ligand-2 V84605 EGFR ligand-2 2737283-20-2
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: sales@invivochem.com Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member